• Oncology
  • Rising incidence across the globe
    Cancer is the leading cause of death worldwide. In 2008, it accounted for approximately 7.6 million deaths (~ 13% of all cases). This number is further projected to rise to over 13 million by 2030. The most frequent types of cancer in 2008 were lung (~ 1.6 million new cases), breast (~ 1.4 million new cases), colorectal (~1.2 million new cases) and stomach cancer (~ 1 million new cases).

    Combination is key to our approach
    Merck Serono Oncology is focused on developing novel cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients.

    Combination is key for Merck Serono not only in developing products that target multiple aspects of the disease process and are suitable for use in combination with established standard therapies, but also for:

    • Combining innovative thinking with intelligent research and technical excellence ─ Merck Serono Oncology has brought together a dedicated group of individuals who can look beyond conventional horizons to explore further possibilities. They have the experience and motivation we need to identify potential therapeutic targets and develop novel cancer treatment strategies.
    • Combining insights, experience and skills ─ Merck Serono is committed to working in partnership with oncology experts, healthcare providers and patients. We strive to meet the needs of patients for better medicines, and to improve access to these medicines by collaborative teamwork and sharing of skills. Moreover, this strategy combines the efficacy of radiotherapy, surgery and medical treatments to create a multidisciplinary approach for the benefit of cancer patients everywhere.

    Erbitux ®